Basalog One

Insulin glargine (rDNA origin)

DM where treatment w/ insulin is required.

SC Adult, adolescent & childn ≥6 yr Individualized dose regimen. Administer once daily at any time but at the same time each day, may be given together w/ oral antidiabetic medications. Switch from NPH insulin bd: Reduce daily basal insulin dose by 20-30% during 1st wk of treatment. Switch from insulin glargine 300 u/mL: Reduce dose by approx 20%.

Hypersensitivity.

Not for IV administration; diabetic ketoacidosis. Insufficient glucose control; tendency to hyper- & hypoglycaemic episodes. Strict medical supervision should be done when transferring a patient to another type or brand of insulin. Perform continuous inj site rotation to reduce risk of developing lipodystrophy & cutaneous amyloidosis; potential risk of delayed insulin absorption & worsened glycaemic control at inj sites w/ these reactions. Risk of hypoglycemia due to sudden change of inj site to an unaffected area; consider blood glucose monitoring after changes in inj site & dose adjustment of antidiabetic medications. May necessitate dose adjustment in case of insulin Ab presence. Expect less nocturnal but early morning hypoglycaemia. Exercise caution & intensify blood glucose monitoring in patients w/ significant stenoses of coronary arteries or of the blood vessels supplying the brain (risk of cardiac or cerebral hypoglycemic complications); proliferative retinopathy, particularly if not treated w/ photocoagulation. Hypoglycaemia warning symptoms may be changed, less pronounced or absent in patients in whom glycaemic control is markedly improved; hypoglycaemia develops gradually; elderly; transferred from animal to human insulin; autonomic neuropathy is present, long history of diabetes; suffering from a psychiatric illness; concurrent treatment w/ certain medications. Monitor & may adjust dose when there is change in the inj area; improved insulin sensitivity; unaccustomed, increased or prolonged physical activity; intercurrent illness (eg, vomiting, diarrhoea); inadequate food intake; missed meals; alcohol consumption; uncompensated endocrine disorders (eg, hypothyroidism & anterior pituitary or adrenocortical insufficiency); concomitant treatment w/ certain medications. Contains metacresol; may cause allergic reactions. Requires intensive metabolic monitoring in case of intercurrent illness. Combination w/ pioglitazone. May impair patient's ability to concentrate & react; may constitute a risk in situations where these abilities are of special importance (eg, driving a car or operating machines). Renal (moderate or severe) & hepatic impairment. Pregnancy & lactation. Childn <6 yr. Elderly ≥65 yr.

Hypoglycaemia. Lipohypertrophy; inj site reactions.

Risk of cardiac failure in combination w/ pioglitazone; discontinue pioglitazone if any deterioration in cardiac symptoms occurs. Blood glucose lowering effect may be enhanced & hypoglycaemia susceptibility may be increased by oral antidiabetic medications, ACE inhibitors, disopyramide, fibrates, fluoxetine, MAOIs, pentoxifylline, propoxyphene, salicylates & sulphonamides. Blood glucose lowering effect may be reduced by corticosteroids, danazol, diazoxide, diuretics, glucagon, INH, oestrogens & progestogens, phenothiazine derivatives, somatropin, sympathomimetics (eg, epinephrine, salbutamol, terbutaline), thyroid hormones, atypical antipsychotics (eg, clozapine, olanzapine), PIs. Blood glucose lowering effect may be potentiated or weakened by β-blockers, clonidine, lithium salts, alcohol. Possible hypoglycaemia followed by hyperglycaemia by pentamidine. Signs of adrenergic counter-regulation may be reduced or absent by β-blockers, clonidine, guanethidine & reserpine.

Insulin Preparations

A10AE04 - insulin glargine ; Belongs to the class of long-acting insulins and analogues for injection. Used in the treatment of diabetes.

POM